September 2, 2021
Astellas Pharma said on September 1 that it has voluntarily paused its global PII study for its investigational gene therapy AT132 covering patients with X-linked myotubular myopathy (XLMTM) due to a serious adverse reaction reported. The company halted screening and...read more